Arrowhead Pharmaceuticals Receives TGA Approval for REDEMPLO (Plozasiran) in Australia for Rare Metabolic Disorder

Key Takeaways

• Australian TGA approves REDEMPLO (plozasiran) as adjunct therapy to reduce triglycerides in adult FCS patients
• Approval expands global access for patients with familial chylomicronemia syndrome, a rare metabolic disorder
• REDEMPLO represents innovative siRNA technology targeting severe hypertriglyceridemia treatment

---

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced that the Australian Therapeutic Goods Administration (TGA) has approved REDEMPLO® (plozasiran), a small interfering RNA (siRNA) medicine, for treating adult patients with familial chylomicronemia syndrome (FCS).

Expanding Treatment Options for Rare Disease

The approval positions REDEMPLO as an adjunct to diet therapy for reducing triglyceride levels in adult patients with FCS, a rare genetic disorder characterized by severely elevated triglyceride levels that can lead to life-threatening pancreatitis.

Familial chylomicronemia syndrome affects approximately 1 in 1 million people worldwide, making effective treatment options critically important for this underserved patient population. The condition results from genetic mutations that impair the body’s ability to break down triglyceride-rich lipoproteins.

siRNA Technology Breakthrough

REDEMPLO’s siRNA mechanism works by targeting specific RNA sequences involved in triglyceride metabolism, offering a novel therapeutic approach for managing severe hypertriglyceridemia. This approval demonstrates the growing acceptance of RNA interference technology in treating rare metabolic disorders.

The Australian approval follows regulatory reviews in other markets, indicating Arrowhead’s commitment to expanding global access for FCS patients who have limited treatment alternatives.

Market Impact and Patient Access

For Arrowhead Pharmaceuticals, this approval strengthens their position in the rare disease market and validates their siRNA platform technology. The company continues advancing their pipeline of RNA-based therapeutics targeting various metabolic and genetic conditions.

The TGA approval enables Australian healthcare providers to prescribe REDEMPLO for eligible FCS patients, potentially improving quality of life and reducing the risk of acute pancreatitis episodes associated with extremely high triglyceride levels.

This regulatory milestone represents significant progress for the rare disease community, particularly patients with FCS who previously had few effective treatment options for managing their condition.

---

Frequently Asked Questions

What is familial chylomicronemia syndrome (FCS)?

FCS is a rare genetic disorder affecting about 1 in 1 million people, characterized by severely elevated triglyceride levels that can cause life-threatening pancreatitis due to genetic mutations impairing triglyceride breakdown.

How does REDEMPLO (plozasiran) work?

REDEMPLO uses small interfering RNA (siRNA) technology to target specific RNA sequences involved in triglyceride metabolism, helping reduce triglyceride levels when used alongside dietary modifications.

When will REDEMPLO be available to Australian patients?

With TGA approval now granted, REDEMPLO can be prescribed by Australian healthcare providers for eligible adult FCS patients as an adjunct to diet therapy, though specific launch timing may depend on commercial availability.